Scinai Immunotherapeutics (SCNI) Total Liabilities (2015 - 2026)
Scinai Immunotherapeutics (SCNI) posted Total Liabilities of $17.6 million for Q1 2026, up 51.28% sequentially from $11.6 million in Q4 2025.
Scinai Immunotherapeutics (SCNI) Total Liabilities (2015 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Total Liabilities for 12 years, with the latest figure at $17.6 million in Q1 2026.
- Quarterly Total Liabilities changed N/A year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (changed N/A YoY) and the FY2025 annual result came in at $11.6 million, down 13.55% from the prior year.
- Total Liabilities climbed to $17.6 million in Q1 2026 per SCNI's latest filing, from $11.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $27.1 million in Q4 2022 and troughed at $11.6 million in Q4 2025.
- A 5-year average of $17.9 million and a median of $17.5 million in 2023 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 11.88% in 2023, down 35.45% in 2023.
- Over 5 years, Total Liabilities stood at $27.1 million in 2022, then plunged by 35.45% to $17.5 million in 2023, then fell by 23.03% to $13.4 million in 2024, then dropped by 13.55% to $11.6 million in 2025, then jumped by 51.28% to $17.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $17.6 million, $11.6 million, and $11.8 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Scinai Immunotherapeutics | 11.49 Mn | -3.10 Bn | -1.12 Mn | 17.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.59 Mn |
| Dec 31, 2025 | 11.63 Mn |
| Jun 30, 2025 | 11.84 Mn |
| Dec 31, 2024 | 13.45 Mn |
| Sep 30, 2024 | 12.26 Mn |
| Jun 30, 2024 | 14.85 Mn |
| Mar 31, 2024 | 17.05 Mn |
| Dec 31, 2023 | 17.47 Mn |
| Sep 30, 2023 | 18.58 Mn |
| Jun 30, 2023 | 19.90 Mn |
| Mar 31, 2023 | 23.29 Mn |
| Dec 31, 2022 | 27.07 Mn |
| Sep 30, 2022 | 21.09 Mn |
| Jun 30, 2022 | 24.45 Mn |
| Dec 31, 2021 | 32.04 Mn |
| Sep 30, 2021 | 25.09 Mn |
| Dec 31, 2020 | 17.70 Mn |
| Sep 30, 2020 | 21.77 Mn |
| Jun 30, 2020 | 24.73 Mn |
| Dec 31, 2019 | 33.49 Mn |